Cara Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus.
STAMFORD, Conn., Oct. 29, 2019 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Tuesday, November 5, 2019, at 4:30 p.m. ET to report third quarter 2019 financial results and provide a corporate update.
